stockrowDyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Free cash flow
Dyne Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$405.1M, compared with −$294.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$480.4M. Over the past ten years it has ranged from −$405.1M (fiscal 2025) to −$4.2M (fiscal 2018) — the current reading is the lowest in ten years. Free cash flow has fallen for 7 consecutive fiscal years. Dyne Therapeutics, Inc. ranks 591st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$405.1M | — |
| FY2024 | −$294.7M | — |
| FY2023 | −$188.9M | — |
| FY2022 | −$156.7M | — |
| FY2021 | −$123.2M | — |
| FY2020 | −$47.7M | — |
| FY2019 | −$13.5M | — |
| FY2018 | −$4.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$131.8M | — |
| Mar 2026 | −$145.1M | — |
| Dec 2025 | −$112.3M | — |
| Sep 2025 | −$91.2M | — |
| 24 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $32.4M |
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| ELVN Enliven Therapeutics, Inc. compare | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| DNLI Denali Therapeutics Inc. compare | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)